Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker
Phase 4
- Conditions
- Arthritis, RheumatoidSpondylitis, Ankylosing
- Interventions
- Registration Number
- NCT01072058
- Lead Sponsor
- University of Sao Paulo
- Brief Summary
The purpose of this study is to determine possible alterations in cardiac function in patients with Rheumatoid Arthritis and Ankylosing Spondylitis under anti-TNF therapy, without clinical heart disfunction at baseline, using highly sensitive non-invasive methods.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Diagnosis of Rheumatoid Arthritis eligible to receive TNF blockers
- Diagnosis of Ankylosing Spondylitis eligible to receive TNF blockers
Exclusion Criteria
- Clinical heart failure
- Chagas'disease
- Stable or unstable angina
- Past history of myocardial infarct
- Systemic árterial hypertension (grade 3)
- Valvulopathy
- Chronic kidney disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description TNF blockers TNF blockers (infliximab, adalimumab, etanercept) -
- Primary Outcome Measures
Name Time Method Development, deterioration ou improvement of subclinical heart dysfunction 0, 6 ,12, 18 and 24 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does TNF-alpha inhibition with blockers like infliximab affect cardiac remodeling in RA and AS patients without baseline dysfunction?
What is the comparative effectiveness of adalimumab, etanercept, and infliximab versus standard-of-care DMARDs in improving cardiac function in RA and AS?
Which biomarkers, such as pro-brain natriuretic peptide or Troponin T, predict cardiac response to TNF blocker therapy in RA and AS patients?
What are the potential adverse cardiac events associated with TNF blockers in RA and AS patients with normal baseline heart function?
How do combination therapies involving TNF blockers and IL-6/JAK inhibitors influence cardiac outcomes in RA and AS compared to monotherapy?
Trial Locations
- Locations (1)
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de são PAulo
🇧🇷Sao Paulo, Brazil
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de são PAulo🇧🇷Sao Paulo, Brazil